Hualan Biological Vaccine

Hualan Biological Vaccine is a prominent Chinese biotechnology company dedicated to the development and commercialization of human vaccines. A subsidiary of Hualan Biological Engineering, the company holds a leading market share in China's influenza vaccine sector, notably being the first domestic manufacturer to receive approval for a quadrivalent influenza vaccine. Its commercial portfolio includes vaccines for rabies, hepatitis B, and meningococcal meningitis, produced in large-scale GMP-compliant facilities. Hualan is actively expanding its pipeline into advanced modalities such as mRNA-based vaccines and recombinant technologies to address emerging infectious diseases. The company is listed on the Shenzhen Stock Exchange and remains a key player in regional biosecurity and public health.